Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Company on $10 million Secondary Public Offering of Cyclacel Pharmaceuticals, Inc.
NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Laidlaw & Company (UK) Ltd. as sole underwriter in a $10 million secondary public offering for Cyclacel Pharmaceuticals, Inc. (“CYCC.” NASDAQ). The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of 2,857,143 shares of common stock at an offering price of $3.50 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Richard Friedman and Stephen Cohen.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Attorneys Mendy Piekarski and Jay Kaplowitz Achieve Successful Settlement of Cryptocurrency Lawsuit - May 21, 2018
- Sichenzia Ross Ference Kesner LLP Represents Pareteum Corporation in $6.1 Million Registered Direct Offering - May 14, 2018
- Partner Harvey Kesner Publishes Article on SEC and Cryptocurrency in Law360 - May 9, 2018